Results 1 to 10 of about 100,521 (261)

S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist [PDF]

open access: yesEndocrinology, 2001
peer reviewedFor many years, our group has been involved in the development of human PRL antagonists. In two recent publications, S179D-human PRL, a human PRL analog designed to mimic a putative S179-phosphorylated human PRL, was reported to be a highly ...
Kelly, Paul A.   +7 more
core   +4 more sources

Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer [PDF]

open access: yesBritish Journal of Cancer, 2006
The aim of this study was to investigate the expression of the protein tyrosine phosphatases (PTP) PRL-1, PRL-2, and PRL-3 in human breast cancer and to evaluate its clinical and prognostic significance. PRL-PTP mRNA expression was examined in malignant (n = 7) and nonmalignant (n = 7) cryoconserved breast tissue samples as well as in eight breast ...
Martin Gotte, L Kiesel, Gotte M
exaly   +3 more sources

PRL PTPs: mediators and markers of cancer progression

open access: yesCancer and Metastasis Reviews, 2008
Aberrant protein tyrosine phosphorylation resulting from the altered activity of protein tyrosine phosphatases (PTPs) is increasingly being implicated in the genesis and progression of human cancer.
Catherine J Pallen
exaly   +2 more sources

PRL Rebuttal

open access: yes, 2023
Rebuttal submitted to Physical Review Letters to a reply by M. Oberlack & S. Hoyas (Apr. 2022) prior to their published Reply (Feb. 2023). The reply refers to the Comments [PRL 130, 069401 (2023)] and [PRL 130, 069402 (2023)]. All arguments put forth by
Frewer, Michael, Khujadze, George
core   +2 more sources

Early effects of PRL on ion conductances in CHO cells expressing PRL receptor

open access: yesAmerican Journal of Physiology-Cell Physiology, 1994
Chinese hamster ovary (CHO-K1) cells were stably transfected with prolactin (PRL) receptor cDNA. These cells (CHO-E32) expressed the long form of functional PRL receptor.
R. Skryma   +6 more
core   +4 more sources

Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity

open access: yesBioorganic and Medicinal Chemistry Letters, 2012
Anthraquinones have been reported as phosphatase inhibitors. Therefore, anthraquinone derivatives were screened to identify a potent phosphatase inhibitor against the phosphatase of regenerating liver-3 (PRL-3).
Young-Min Han   +2 more
exaly   +2 more sources

PRL: A probabilistic relational language [PDF]

open access: yesMachine Learning, 2006
zbMATH Open Web Interface contents unavailable due to conflicting licenses.
Lise Getoor, John Grant
openaire   +1 more source

Nanobodies selectively immunoprecipitate PRL-3 from HEK293T cell lysate and IP HA-PRL-3 comparatively to commercially available anti-PRL-3 antibodies.

open access: yes, 2023
(A) Nanobody 19 pulls down 3XFLAG-PRL-3 with minimal to no pulldown of 3XFLAG-PRL-1 or 3XFLAG-PRL-2. Successful nanobody coupling to Dynabeads was verified using an antibody against the C-terminal 6XHis-tag present on each nanobody. (B) Nanobody 19 pulls
K. Martin Chow (772610)   +7 more
core   +1 more source

Anti-PRL-3 nanobodies partially interact with the PRL-3 active site and site of CNNM3 CBS-domain binding.

open access: yes, 2023
(A) Phosphatase activity of PRL-3 alone or in complex with nanobody 91, against a generic diFMUP substrate. DiFMUP fluoresces when phosphate is released. The graph shows normalized fluorescence to PRL-3 alone, n = 12 ± standard deviation.
K. Martin Chow (772610)   +7 more
core   +1 more source

PRL-3 localization assessed by nanobody 26 and 19 is altered by N-terminal 3XFLAG and GFP tags.

open access: yes, 2023
(A) Immunofluorescence of HCT116 cells transfected with CMV:3XFLAG-PRL-3, CMV:GFP-PRL-3, CMV:HA-PRL-3, or CMV-PRL-3, as indicated. Cells were stained with anti-PRL-3 nanobody 26 or 19 (HA) followed by an anti-alpaca VHH coupled to Alexa594 secondary ...
K. Martin Chow (772610)   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy